Erfahrungsheilkunde 2014; 63(2): 84-92
DOI: 10.1055/s-0033-1357625
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Die Behandlung mit natur-identischen Hormonen

Elke Schwesig-Seebach
Further Information

Publication History

Publication Date:
28 April 2014 (online)


Natur-identische Hormone werden definiert als Hormone, die exakt in der molekularen Struktur hergestellt werden, in der sie auch vom menschlichen Organismus produziert werden. Die Therapie mit natur-identischen Hormonen bietet eine Vielzahl von Einsatzmöglichkeiten, ohne die möglichen Nebenwirkungen synthetischer Hormone. Bei richtiger Anwendung können sie z. B. Wechseljahresbeschwerden, Erschöpfungssyndrome oder komplementär in der Krebstherapie wertvolle Dienste leisten.


Nature-identical hormones are defined as hormones, which are produced exactly in the molecular structure as it is the case in the human organism. The therapy with nature-identical hormones offers a variety of possible applications without the side effects of synthetic hormones. When used correctly, they can be of great value e. g. in the case of climacteric discomforts, fatigue syndromes or as a complement in cancer therapy.

  • Literatur

  • 1 Rapp SR et al. WHIMS Investigators. Womens Health Initiative Memory Study (WHIMS) JAMA 2003;
  • 2 Magee PJ, Rowland I. Soy products in the management of breast cancer. Curr Opin Clin Nutr Metab Care 2012; 15 (6): 586-591
  • 3 Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells. Inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 1998; 28 (6): 360-369
  • 4 Rosane GMC, Webb CM et al. Natural progesterone, but not Medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise induced myocardial ischemia in postmenopausal women. J Am Coll Card 2000; 36 (7): 2154-2159
  • 5 Schmidt M, Renner C, Loffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol 1998; 158 (3): 401-407
  • 6 Guo L, Meng J, Yilamu D et al. Significance of ERbeta expression in different molecular subtypes of breast cancer. Diagn Pathol 2014; 9 (1): 20
  • 7 Patnayak R, Jena A, Parthasarathy S et al. Solid and cystic papillary neoplasm of pancreas: A clinic-pathological and immunohistochemical study: A tertiary care center experience. South Asian J Cancer 2013; 2 (3): 153-157
  • 8 Ahn SH, Kim HJ, Han W et al. Effect modification of hormonal therapy by p53 status in invasive breast cancer. J Breast Cancer 2013; 16 (4): 386-394
  • 9 Saito K, Furukawa E, Kobayashi M et al. Degradation of estrogen receptor á in activated blastocysts is associated with implantation in the delayed-implantation mouse model. Mol Hum Reprod 2014; [E-Pub aheadof print] PMID: 24442344
  • 10 Brisken C. Is progesterone a neutral or protective factor for breast cancer?. Nat Rev Cancer 2014; 14 (2): 146
  • 11 Mahmud K. Natural hormone therapy for menopause. Gynecol Endocrinol 2010; 26 (2): 81-85
  • 12 Ribot C, Trémollieres F. Hormone replacement therapy in postmenopausal women: all the treatments are not the same. Gynecol Obstet Fertil 2007; 35 (5): 388-397
  • 13 Plechner AJ. Cortisol abnormality as a cause of elevated estrogen and immune destabilization: insights for human medicine from a veterinary perspective. Med Hypotheses 2004; 62 (4): 575-581
  • 14 Titus MA, Li Y, Kozyreva OG et al. 5á-reductase type 3 enzyme in benign and malignant prostate. Prostate 2014; 74 (3): 235-249
  • 15 Kumagai J, Hofland J, Erkens-Schulze S et al. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate 2013; 73 (15): 1636-1650